TARA Protara Therapeutics Forecast, Technical & Fundamental Analysis
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases... Show more
TARA is expected to report earnings to rise 11.06% to -34 cents per share on October 29
Q3'26
Est.
$-0.34
Q1'26
Beat
by $0.03
Q4'25
Missed
by $0.02
Q3'25
Beat
by $0.07
Q2'25
Beat
by $0.05
The last earnings report on May 13 showed earnings per share of -31 cents, beating the estimate of -34 cents. With 279.96K shares outstanding, the current market capitalization sits at 224.25M.
A.I. Advisor
published General Information
General Information
a clinical-stage company, which engages in developing treatments for rare and specialty diseases with significant unmet needs.
A.I.dvisor indicates that over the last year, TARA has been loosely correlated with AMLX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if TARA jumps, then AMLX could also see price increases.
The Moving Average Convergence Divergence (MACD) for TARA turned positive on August 04, 2026. Looking at past instances where TARA's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 69 cases where TARA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TARA advanced for three days, in of 214 cases, the price rose further within the following month. The odds of a continued upward trend are .
TARA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 127 cases where TARA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TARA as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TARA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.238) is normal, around the industry mean (20.076). P/E Ratio (0.000) is within average values for comparable stocks, (25.135). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.546). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (412.299).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. TARA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TARA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
